CSF biomarkers for improved prognostic accuracy in acute CNS disease

References

• Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 13: 81–84
   Google Scholar
• Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet 1975; 1: 480–484
   PubMed Web of Science ®Google Scholar
• Wijdicks EF, Bamlet WR, Maramattom By, et al. Validation of a new coma scale: The FOUR score. Ann Neurol 2005; 58: 585–593
   PubMed Web of Science ®Google Scholar
• Wijdicks EF. Clinical scales for comatose patients: The Glasgow coma scale in historical context and the new FOUR Score. Rev Neurol Dis 2006; 3: 109–117
   PubMedGoogle Scholar
• Ducrocq SC, Meyer PG, Orliaguet GA, et al. Epidemiology and early predictive factors of mortality and outcome in children with traumatic severe brain injury: Experience of a French pediatric trauma center. Pediatr Crit Care Med 2006; 7: 461–407
   PubMed Web of Science ®Google Scholar
• Atzema C, Mower WR, Hoffman JR, et al. Prevalence and prognosis of traumatic intraventricular hemorrhage in patients with blunt head trauma. ] Trauma 2006; 60: 1010–1007
   PubMedGoogle Scholar
• Chung CY, Chen CL, Cheng PT, et al. Critical score of Glasgow coma scale for pediatric traumatic brain injury. Pediatr Neurol 2006; 34: 379–387
   PubMed Web of Science ®Google Scholar
• Tien HC, Cunha JR, Wu SN, et al. Do trauma patients with a Glasgow coma scale score of 3 and bilateral fixed and dilated pupils have any chance of survival?] Trauma 2006; 60: 274–208
   PubMedGoogle Scholar
• McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 2006; 100: 229–235
   PubMed Web of Science ®Google Scholar
• Martin R, Bielekova B, Hohlfeld R, et al. Biomarkers in multiple sclerosis. Dis Markers 2006; 22: 183–105
   PubMed Web of Science ®Google Scholar
• Felgenhauer K, Beuche W, eds. Labordiagnostik Neurologischer Erkrankungen, Stuttgart: Thieme, 1999
   Google Scholar
• Reiber H. The discrimination between different blood—CSF barrier dysfunctions and inflammatory reactions of the CNS by a recent evaluation graph for the protein profile of cerebrospinal fluid. J Neurol 1980; 224: 89–99
   PubMed Web of Science ®Google Scholar
• Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001; 310: 173–186
   PubMed Web of Science ®Google Scholar
• Thompson EJ. The CSF Proteins: A Biochemical Approach, Amsterdam: Elsevier, 1988
   Google Scholar
• Petzold A. Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005; 233: 183–198
   PubMed Web of Science ®Google Scholar
• Kleindienst A, Ross Bullock M. A critical analysis of the role of the neurotrophic protein 5100B in acute brain injury.] Neurotrauma 2006; 23: 1185–1300
   PubMed Web of Science ®Google Scholar
• Felgenhauer K. Proteinsize and cerebrospinal fluid composition. Klin Woch 1974; 52: 1158–1164
   PubMedGoogle Scholar
• Rapoport St. Neurobiology of Cerebrospinal Fluid, New York: Plenum, 1983: pp. 233–245
   Google Scholar
• Nilsson C, Stahlberg F, Thomsen C, et al. Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging. Am] Physiol 1992; 262: R20—R24
   Google Scholar
• Reiber H. Flow rate of cerebrospinal fluid (CSF) — a concept common to normal blood—CSF barrier function and to dysfunc-tion in neurological diseases. ] Neurol Sci 1994; 122: 189–203
   PubMed Web of Science ®Google Scholar
• Petzold A, Keir G, Sharpe LT. Spectrophotometry for xantho-chromia. N Engl J Med 2004; 351: 1695–1696
   PubMed Web of Science ®Google Scholar
• Petzold A, Sharpe LT, Keir G. Spectrophotometry for cerebrosp-inal fluid pigment analysis. Neurocrit Care 2006,4: 153–162
   PubMed Web of Science ®Google Scholar
• UK National External Quality Assessment Scheme for Immunochemistry Working Group. National guidelines for analysis of cerebrospinal fluid for bilirubin in suspected subarachnoid haemorrhage. Ann Clin Biochem 2003, 40: 481–408
   PubMed Web of Science ®Google Scholar
• Rejdak K, Petzold A, Sharpe MA, et al. Cerebrospinal fluid nitrite/ nitrate correlated with oxyhemoglobin and outcome in patients with subarachnoid hemorrhage. ] Neurol Sci 2004; 219: 71–76
   PubMed Web of Science ®Google Scholar
• Tisdall MM, Smith M. Cerebral microdialysis: Research technique or clinical tool. Br] Anaesth 2006; 97: 18–25
   PubMed Web of Science ®Google Scholar
• Rosengren LE, Karlsson JE, Karlsson JO, et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996; 67: 2013-2018
   PubMed Web of Science ®Google Scholar
• Petzold A, Keir G, Green AJ, et al. A specific [LISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003; 278: 179–190
   PubMed Web of Science ®Google Scholar
• Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003; 987: 25–31
   PubMed Web of Science ®Google Scholar
• Petzold A, Rejdak K, Plant GT. Axonal degeneration and inflammation in acute optic neuritis. J Neurol Neurosurg Psychiatry 2004; 75: 1178–1180
   PubMed Web of Science ®Google Scholar
• Shaw G, Yang C, Ellis R, et al. Hyperphosphorylated neurofila-ment NF-H is a serum biomarker for axonal injury. Biochem Biophys Res Commun 2005; 336: 1268–1277
   PubMed Web of Science ®Google Scholar
• Petzold A, Stiefel D, Copp AJ. Amniotic fluid brain-specific proteins are biomarkers for spinal cord injury in experimental myel omen ingocele. J Neurochem 2005; 95: 594–508
   PubMed Web of Science ®Google Scholar
• Lee MK, Cleveland DW. Neuronal intermediate filaments. Ann Rev Neurosci 1996; 19: 187–217
   PubMed Web of Science ®Google Scholar
• Shaw G. Neurofilaments, Berlin: Springer-Verlag, 1998
   Google Scholar
• Yuan A, Rao MV, Sasaki T, et al. Alpha-internexin is structurally and functionally associated with the neurofilament triplet proteins in the mature CNS. J Neurosci 2006; 26: 10006–10019
   PubMed Web of Science ®Google Scholar
• Petzold A. Neurofilaments: A biomarker for axonal degeneration in J. J. Haddad (2008). Neuroimmune interactions and mechan-isms, in Binder MD, Hirokawa N, Windhorst U and Hirch ML (eds) Encyclopedic Reference of Neuroscience. Neuro-immunology, 1st edn, Vol. 1, Berlin: Springer-Verlag
   Google Scholar
• van Geel WJ, Rosengren LE, Verbeek MM. An enzyme immunoassay to quantify neurofilament light chain in cerebrosp-inal fluid. J Immunol Methods 2005; 296: 179–185
   PubMed Web of Science ®Google Scholar
• Petzold A, Shaw G. Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain. ] Immunol Methods 2007; 319: 34–40
   PubMed Web of Science ®Google Scholar
• Petzold A, Rejdak K, Belli A, et al. Axonal pathology in subarachnoid and intracerebral hemorrhage. J Neurotrauma 2005,22: 407–414
   PubMed Web of Science ®Google Scholar
• Petzold A, Keir G, Kay A, et al. Axonal damage and outcome in subarachnoid hemorrhage. ] Neurol Neurosurg Psychiatry 2006; 77: 753–758
   PubMed Web of Science ®Google Scholar
• Nylen K, Csajbok LZ, Ost M, et al. CSF-neurofilament correlates with outcome after aneurysmal subarachnoid hemorrhage. Neurosci Lett 2006; 404: 132–106
   PubMed Web of Science ®Google Scholar
• Rosen H, Karlsson JE, Rosengren L. CSF levels of neurofilament is a valuable predictor of long-term outcome after cardiac arrest. J Neurol Sci 2004; 221: 19–24
   PubMed Web of Science ®Google Scholar
• Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow outcome scale and the extended Glasgow outcome scale: Guidelines for their use. ] Neurotrauma 1998,15: 573–585
   PubMed Web of Science ®Google Scholar
• Sugawara T, Lewen A, Noshita N, et al. Effects of global ischemia duration on neuronal, astroglial, oligodendroglial, and microglial reactions in the vulnerable hippocampal CA1 subregion in rats. J Neurotrauma 2002; 19: 85–98
   PubMed Web of Science ®Google Scholar
• Dugan LL, Kim-Han JS. Astrocyte mitochondria in in vitro models of ischemia. J Bioenerg Biomembr 2004,36: 317–321
   PubMed Web of Science ®Google Scholar
• Giffard RG, Papadopoulos MC, van Hooft JA, et al. The electrogenic sodium bicarbonate cotransporter: Developmental expression in rat brain and possible role in acid vulnerability. J Neurosci 2000; 20: 1001–1008
   PubMed Web of Science ®Google Scholar
• Albrechtsen M, Bock E. Quantification of glial fibrillary acidic protein (GFAP) in human-body fluids by means of ELISA employing a monoclonal-antibody. J Neuroimmunol 1985; 8: 301–309
   PubMed Web of Science ®Google Scholar
• Rosengren LE, Ahlsen G, Belfrage M, et al. A sensitive ELISA for glial fibrillary acidic protein: Application in CSF of children. J Neurosci Methods 1992; 44: 113–119
   PubMed Web of Science ®Google Scholar
• Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: Application in CSF of adults. J Neurosci Methods 1994; 51: 197–204
   PubMed Web of Science ®Google Scholar
• Missler U, Wiesmann M, Wittmann G, et al. Measurement of glial fibrillary acidic protein in human blood: Analytical method and preliminary clinical results. Clin Chem 1999; 45: 138–141
   PubMed Web of Science ®Google Scholar
• van Geel WJ, de Reus HP, Nijzing H, et al. Measurement of glial fibrillary acidic protein in blood: An analytical method. Clin Chim Acta 2002; 326: 151–154
   PubMed Web of Science ®Google Scholar
• Nylen K, Ost M, Csajbok LZ, et al. Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci 2006; 240: 85–91
   PubMed Web of Science ®Google Scholar
• Gurnett CA, Landt M, Wong M. Analysis of cerebrospinal fluid glial fibrillary acidic protein after seizures in children. Epilepsia 2003; 44: 1455–1408
   PubMed Web of Science ®Google Scholar
• Petzold A, Keir G, Green AJ, et al. An ELISA for glial fibrillary acidic protein. ] Immunol Methods 2004; 287: 169–177
   PubMed Web of Science ®Google Scholar
• Petzold A, Keir G, Kerr M, et al. Early identification of secondary brain damage in subarachnoid hemorrhage: A role for glial fibrillary acidic protein. ] Neurotrauma 2006; 23: 1179–1184
   PubMed Web of Science ®Google Scholar
• Vos PE, van Gils M, Beems T, et al. Increased GFAP and S100beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity. Eur J Neurol 2006; 13: 632–608
   PubMed Web of Science ®Google Scholar
• Vos PE, Lamers KJ, Hendriks JC, et al. GI ial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 2004; 62: 1303–1310
   PubMed Web of Science ®Google Scholar
• Wunderlich MT, Wallesch CW, Goertler M. Release of glial fibrillary acidic protein is related to the neurovascular status in acute ischemic stroke. Eur J Neurol 2006; 13: 1118–1123
   PubMed Web of Science ®Google Scholar
• Foerch C, Curdt I, Yan B, et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. ] Neurol Neurosurg Psychiatry 2006; 77: 181–104
   PubMed Web of Science ®Google Scholar
• Kursula P. Structural properties of proteins specific to the myelin sheath. Amino Acids 2007; to be published — this paper is listed on pubmed (PMID 17250651) as Amino Acids 2006, Dec. 22
   Google Scholar
• Berger RP, Dulani T, Adelson PD, et al. Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers: A possible screening tool. Pediatrics 2006; 117: 325–332
   PubMed Web of Science ®Google Scholar
• Davies L, McLeod JG, Muir A, et al. Diagnostic value of cerebrospinal fluid myelin basic protein in patients with neurological illness. Clin Exp Neurol 1987; 24: 5–10
   PubMedGoogle Scholar
• Matias-Guiu J, Martinez-Vazquez J, Ruibal A, et al. Myelin basic protein and creatine kinase BB isoenzyme as CSF markers of intracranial tumors and stroke. Acta Neurol Scand 1986; 73: 461–405
   PubMed Web of Science ®Google Scholar
• Noseworthy TW, Anderson BJ, Noseworthy AF, et al. Cerebrospinal fluid myelin basic protein as a prognostic marker in patients with head injury. Crit Care Med 1985; 13: 743–706
   PubMed Web of Science ®Google Scholar
• Beems T, Simons KS, van Geel WJ, et al. Serum- and CSF-concentrations of brain specific proteins in hydrocephalus. Acta Neurochir 2003; 145: 37–43
   PubMed Web of Science ®Google Scholar
• Longatti PL, Guida F, Agostini S, et al. The CSF myelin basic protein in pediatric hydrocephalus. Childs Nerv Syst 1994; 10: 96–98
   PubMed Web of Science ®Google Scholar
• Levin SD, Hoyle NR, Brown JR, et al. Cerebrospinal fluid myelin basic protein immunoreactivity as an indicator of brain damage in children. Dev Med Child Neurol 1985; 27: 807–813
   PubMed Web of Science ®Google Scholar
• Sutton LN, Wood JH, Brooks BR, et al. Cerebrospinal fluid myelin basic protein in hydrocephalus. ] Neurosurg 1983; 59: 467–470
   PubMed Web of Science ®Google Scholar
• Hirashima Y, Endo S, Nakamura S, et al. Cerebrospinal fluid membrane-bound tissue factor and myelin basic protein in the course of vasospasm after subarachnoid hemorrhage. Neurol Res 2001; 23: 715–720
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Yamada M, Kanayama T, et al. Myelin basic protein in the cerebrospinal fluid of patients with brain tumors. Neurosurgery 1994; 34: 825–833
   PubMed Web of Science ®Google Scholar
• Noppe M, Crols R, Andries D, et al. Determination in human cerebrospinal fluid of glial fibrillary acidic protein, S-100 and myelin basic protein as indices of non-specific or specific central nervous tissue pathology. Clin Chim Acta 1986; 155: 143–150
   PubMed Web of Science ®Google Scholar
• Siegal T, Ovadia H, Yatsiv I, et al. CSF myelin basic protein levels in leptomeningeal metastases. Relationship to disease activity. J Neurol Sci 1987; 78: 165–173
   PubMed Web of Science ®Google Scholar
• Garcia-Alix A, Cabanas F, Pellicer A, et al. Neuron-specific enolase and myelin basic protein: Relationship of cerebrospinal fluid concentrations to the neurologic condition of asphyxiated full-term infants. Pediatrics 1994; 93: 234–240
   PubMed Web of Science ®Google Scholar
• Kohlschutter A. Myelin basic protein in cerebrospinal fluid from children. Eur J Pediatr 1978; 127: 155–161
   PubMed Web of Science ®Google Scholar
• Thyss A. Myelin basic protein in CSF of children receiving intrathecal chemotherapy. J Clin Oncol 1986; 4: 1569–1500
   PubMed Web of Science ®Google Scholar
• Pinkerton CR, Chessells JM, Hoyle NR. Myelin basic protein concentrations in the CSF of children receiving methotrexate. ]Clin Oncol 1986; 4: 112–103
   Web of Science ®Google Scholar
• Neijstrom E, Gabriel DA, Capizzi RL. High-dose methotrexate-induced neurotoxicity associated with elevation of CSF myelin basic protein. ] Clin Oncol 1985; 3: 593–504
   PubMed Web of Science ®Google Scholar
• Clark AW, Cohen SR, Nissenblatt MJ, et al. Paraplegia following intrathecal chemotherapy: Neuropathologic findings and eleva-tion of myelin basic protein. Cancer 1982; 50: 42–47
   PubMed Web of Science ®Google Scholar
• Strand T, Ailing C, Karlsson B, et al. Brain and plasma proteins in spinal fluid as markers for brain damage and severity of stroke. Stroke, 1984; 15: 138–144
   PubMed Web of Science ®Google Scholar
• Whitaker JN, Lisak RP, Bashir RM, et al. Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders. Ann Neurol 1980; 7: 58–64
   PubMed Web of Science ®Google Scholar
• Lamers KJ, van Engelen BG, Gabreels FJ, et al. Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurol Scand 1995; 92: 247–251
   PubMed Web of Science ®Google Scholar
• Jacque C, Delassalle A, Rancurel G, et al. Myelin basic protein in CSF and blood. Relationship between its presence and the occurrence of a destructive process in the brains of encephalitic patients. Arch Neurol 1982; 39: 557–560
   PubMedGoogle Scholar
• Ruutiainen J, Arnadottir T, Molnar G, et al. Myelin basic protein antibodies in the serum and CSF of multiple sclerosis and subacute sclerosing panencephalitis patients. Acta Neurol Scand 1981; 64: 196–206
   PubMed Web of Science ®Google Scholar
• Pan itch HS, Hooper CJ, Johnson KP. CSF antibody to myelin basic protein. Measurement in patients with multiple sclerosis and subacute sclerosing panencephalitis. Arch Neurol 1980; 37: 206–209
   PubMedGoogle Scholar
• Alling C, Karlsson B, Vallfors B. Increase in myelin basic protein in CSF after brain surgery. ] Neurol 1980; 223: 225–230
   PubMed Web of Science ®Google Scholar
• Whitaker JN. Myelin basic protein in cerebrospinal fluid and other body fluids. Mult Scler 1998,4: 16–21
   PubMed Web of Science ®Google Scholar
• Mandel P, Metals P. Les acides nucletiques du plasma sanguin chez l'homme. C R Acad Sci Paris 1948,142: 241–243
   Google Scholar
• Swaminathan R, Butt AN. Circulating nucleic acids in plasma and serum: Recent developments. Ann NY Acad Sci 2006; 1075: 1–9
   PubMed Web of Science ®Google Scholar
• Lam NY, Rainer TH, Wong LK, et al. Plasma DNA as a prognostic marker for stroke patients with negative neuroimaging within the first 24 h of symptom onset. Resuscitation 2006; 68: 71–78
   PubMed Web of Science ®Google Scholar
• Fletcher L, Rider CC, Taylor CB. Enolase isoenzymes. III. Chromatographic and immunological characteristics of rat brain enolase. Biochim Biophys Acta 1976; 452: 245–252
   PubMed Web of Science ®Google Scholar
• Schmechel D, Marangos PJ, Zis AP, et al. Brain endolases as specific markers of neuronal and glial cells. Science 1978; 199: 313–305
   PubMed Web of Science ®Google Scholar
• Schneider J. Tumor markers in detection of lung cancer. Adv Clin Chem 2006; 42: 1–41
   PubMed Web of Science ®Google Scholar
• Mokuno K, Kato K, Kawai K, et al. Neuron-specific enolase and 5-100 protein levels in cerebrospinal fluid of patients with various neurological diseases. ] Neurol Sci 1983; 60: 443–451
   PubMed Web of Science ®Google Scholar
• Jacobi C, Reiber H. Clinical relevance of increased neuron-specific enolase concentration in cerebrospinal fluid. Clin Chim Acta 1988; 177: 49–54
   PubMed Web of Science ®Google Scholar
• Wong M, Ess K, Landt M. Cerebrospinal fluid neuron-specific enolase following seizures in children: Role of etiology. ] Child Neurol 2002; 17: 261–204
   PubMed Web of Science ®Google Scholar
• Tanabe T, Suzuki D, Hara K, et al. Cerebrospinal fluid and serum neuron-specific enolase levels after febrile seizures. Epilepsia 2001; 42: 504–507
   PubMed Web of Science ®Google Scholar
• Correale J, Rabinowicz AL, Heck CN, et al. Status epilepticus increases CSF levels of neuron-specific enolase and alters the blood—brain barrier. Neurology 1998; 50: 1388–1391
   PubMed Web of Science ®Google Scholar
• Palmio J, Peltola J, Vuorinen P, et al. Normal CSF neuron-specific enolase and S-100 protein levels in patients with recent non-complicated tonic—clonic seizures.] Neurol Sci 2001; 183: 27–31
   PubMed Web of Science ®Google Scholar
• Dorta-Contreras AJ, Tabio-Valdes E, Tabio-Valdes A, et al. Non increased neuron-specific enolase concentration in cerebrospinal fluid during first febrile seizures and a year follow-up in pediatric patients. Arq Neuropsiquiatr 1998; 56: 540–504
   PubMed Web of Science ®Google Scholar
• Lima JE, Takayanagui OM, Garcia LV, et al. Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders. Braz J Med Biol Res 2004; 37: 19–26
   PubMed Web of Science ®Google Scholar
• Mokuno K, Kiyosawa K, Sugimura K, et al. Prognostic value of cerebrospinal fluid neuron-specific enolase and S-100b protein in Guillain—Barre syndrome. Acta Neurol Scand 1994; 89: 27–30
   PubMed Web of Science ®Google Scholar
• Karkela J, Bock E, Kaukinen S. CSF and serum brain-specific creatine kinase isoenzyme (CK-BB), neuron-specific enolase (NSE) and neural cell adhesion molecule (NCAM) as prognostic markers for hypoxic brain injury after cardiac arrest in man. J Neurol Sci 1993; 116: 100–109
   PubMed Web of Science ®Google Scholar
• Pleines UE, Morganti-Kossmann MC, Rancan M, et al. S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. ] Neurotrauma 2001; 18: 491–408
   PubMed Web of Science ®Google Scholar
• Ross SA, Cunningham RT, Johnston CF, et al. Neuron-specific enolase as an aid to outcome prediction in head injury. Br] Neurosurg 1996; 10: 471–406
   PubMed Web of Science ®Google Scholar
• Berger RP, Pierce MC, Wisniewski SR, et al. Neuron-specific enolase and S10013 in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatrics 2002; 109: E31
   PubMed Web of Science ®Google Scholar
• Shore PM, Berger RP, Varma S, et al. Cerebrospinal fluid biomarkers versus Glasgow coma scale and Glasgow outcome scale in pediatric traumatic brain injury: The role of young age and inflicted injury. ] Neurotrauma 2007; 24: 75–86
   PubMed Web of Science ®Google Scholar
• Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965; 19: 739–744
   PubMed Web of Science ®Google Scholar
• Donato R. S100: A multigenic family of calcium-modulated proteins of the [F-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001; 33: 637–668
   PubMed Web of Science ®Google Scholar
• Hattori M, Fujiyama A, Taylor TD, et al. The DNA sequence of human chromosome 21. Nature 2000; 405: 311–309
   PubMed Web of Science ®Google Scholar
• Heizmann CW, Cox JA. New perspectives on S100 proteins: A multi-functional Ca2+-, Zn2+- and Cu2+-binding protein family. Biometals 1998; 11: 383–397
   PubMed Web of Science ®Google Scholar
• Green AJ, Keir G, Thompson EJ. A specific and sensitive [LISA for measuring S-100b in cerebrospinal fluid. J Immunol Methods 1997; 205: 35–41
   PubMed Web of Science ®Google Scholar
• Sindic CJ, Chalon MP, Cambiaso CL, et al. Assessment of damage to the central nervous system by determination of S-100 protein in the cerebrospinal fluid. ] Neurol Neurosurg Psychiatry 1982; 45: 1130–1105
   PubMed Web of Science ®Google Scholar
• Michetti F, Massaro A, Russo G, et al. The S-100 antigen in cerebrospinal fluid as a possible index of cell injury in the nervous system. Neurol Sci 1980; 44: 259–263
   Web of Science ®Google Scholar
• Heizmann CW. S100B protein in clinical diagnostics: Assay specificity. Clin Chem 2004; 50: 249–251
   PubMed Web of Science ®Google Scholar
• Torabian S, Kashani-Sabet M. Biomarkers for melanoma. Curr Opin Oncol 2005; 17: 167–171
   PubMed Web of Science ®Google Scholar
• Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S10013 in malignant melanoma. Clin Biochem 2004; 37: 512–508
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Tumani H, Otto M, et al. Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy. Epilepsy Res 1999; 36: 75–82
   PubMed Web of Science ®Google Scholar
• Stroick M, Fatar M, Ragoschke-Schumm A, et al. Protein S-100B — a prognostic marker for cerebral damage. Curr Med Chem 2006, 13: 3053–3060
   PubMed Web of Science ®Google Scholar
• Herrmann M, Ehrenreich H. Brain derived proteins as markers of acute stroke: Their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor Neurol Neurosci 2003; 21: 177–190
   PubMed Web of Science ®Google Scholar
• Jonsson H. S100B and cardiac surgery: Possibilities and limita-tions. Restor Neurol Neurosci 2003; 21: 151–107
   PubMed Web of Science ®Google Scholar
• Petzold A, Keir G, Lim D, et al. CSF and serum S10013: Release and wash-out pattern. Brain Res Bull 2003; 61: 281–285
   PubMed Web of Science ®Google Scholar
• Kay AD, Petzold A, Kerr M, et al. Cerebrospinal fluid apolipoprotein E concentration decreases after traumatic brain injury. ] Neurotrauma 2003; 20: 243–250
   PubMed Web of Science ®Google Scholar
• Kay AD, Petzold A, Kerr M, et al. Alterations in cerebrospinal fluid apolipoprotein E and amyloid. J Neurotrauma 2003; 20: 943–952
   PubMed Web of Science ®Google Scholar
• Hayakata T, Shiozaki T, Tasaki O, et al. Changes in CSF S10013 and cytokine concentrations in early-phase severe traumatic brain injury. Shock 2004; 22: 102–107
   PubMed Web of Science ®Google Scholar
• Kay A, Petzold A, Kerr M, et al. Decreased cerebrospinal fluid apolipoprotein E after subarachnoid hemorrhage: Correlation with injury severity and clinical outcome. Stroke 2003; 34: 637–642
   PubMed Web of Science ®Google Scholar
• Kay A, Petzold A, Kerr M, et al. Temporal alterations in cerebrospinal fluid amyloid beta-protein and apolipoprotein E after subarachnoid hemorrhage. Stroke 2003; 34: e240—e243
   Google Scholar
• Goedert M, Spillantini MG, Jakes R, et al. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989; 3: 519–526
   PubMed Web of Science ®Google Scholar
• Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. ] Neurochem 1993; 61: 1828–1834
   PubMed Web of Science ®Google Scholar
• J in K, Takeda A, Shiga Y, et al. CSF tau protein: A new prognostic marker for Guillain-Barre syndrome. Neurology 2006; 67: 1470–1402
   PubMed Web of Science ®Google Scholar
• Sussmuth SD, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): A blood—CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 2001; 300: 95–98
   PubMed Web of Science ®Google Scholar
• Petzold A, Hinds N, Murray NM, et al. CSF neurofilament levels: A potential prognostic marker in Guillain—Barre syndrome. Neurology 2006; 67: 1071–1003
   PubMed Web of Science ®Google Scholar
• Ost M, Nylen K, Csajbok L, et al., Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 2006; 67: 1600–1604
   PubMed Web of Science ®Google Scholar
• Zemlan FP, Rosenberg WS, Luebbe PA, et al. Quantification of axonal damage in traumatic brain injury: Affinity purification and characterization of cerebrospinal fluid tau proteins.] Neurochem 1999; 72: 741–750
   PubMed Web of Science ®Google Scholar
• Zemlan FP, Jauch EC, Mulchahey JJ, et al. C-tau biomarker of neuronal damage in severe brain injured patients: Association with elevated intracranial pressure and clinical outcome. Brain Res 2002; 947: 131–109
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Roberts GW, Graham DI. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med 1995; 1: 135–137
   PubMed Web of Science ®Google Scholar
• Blennow K, de Leon MJ, Zetterberg H. Alzheimer 's disease. Lancet 2006; 368: 387–403
   PubMed Web of Science ®Google Scholar
• Hesse C, Rosengren L, Vanmechelen E, et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis 2000; 2: 199–206
   PubMedGoogle Scholar
• Olsson A, Csajbok L, Ost M, et al. Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. ] Neurol 2004; 251: 870–806
   PubMed Web of Science ®Google Scholar
• Franz G, Beer R, Kampfl A, et al. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 2003; 60: 1457–1461
   PubMed Web of Science ®Google Scholar
• Emmerling MR, Morganti-Kossmann MC, Kossmann T, et al. Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injury. Ann NY Acad Sci 2000; 903: 118–122
   PubMed Web of Science ®Google Scholar
• Sjogren M, Gisslen M, Vanmechelen E, et al. Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci Lett 2001; 314: 33–36
   PubMed Web of Science ®Google Scholar
• Blennow K, Nellgard B. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 2004; 62: 159
   PubMed Web of Science ®Google Scholar
• Raby CA, Morganti-Kossmann MC, Kossmann T, et al. Traumatic brain injury increases beta-amyloid peptide 1-42 in cerebrospinal fluid. ] Neurochem 1998; 71: 2505–2509
   PubMed Web of Science ®Google Scholar
• Pritchard J, Hughes RA, Rees JH, et al. Apolipoprotein E genotypes and clinical outcome in Guillain—Barre syndrome. J Neurol Neurosurg Psychiatry 2003; 74: 971–903
   PubMed Web of Science ®Google Scholar
• Martinez-Gonzalez NA, Sudlow CL. Effects of apolipoprotein E genotype on outcome after ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2006; 77: 1329–1335
   PubMed Web of Science ®Google Scholar
• Diaz-Arrastia R, Baxter VK. Genetic factors in outcome after traumatic brain injury: What the human genome project can teach us about brain trauma. ] Head Trauma Rehabil 2006; 21: 361–374
   PubMed Web of Science ®Google Scholar
• Teasdale GM, Nicoll JA, Murray G, et al. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997; 350: 1069–1071
   PubMed Web of Science ®Google Scholar
• Vance JE, Karten B, Hayashi H. Lipid dynamics in neurons. Biochem Soc Trans 2006; 34: 399–403
   PubMed Web of Science ®Google Scholar
• Nishino S. The hypocretin/orexin system in health and disease. Biol Psychiatry 2003; 54: 87–95
   PubMed Web of Science ®Google Scholar
• Nishino S, Fujiki N. Neuropeptides as possible targets in sleep disorders. Expert Opin Ther Targets 2007; 11: 37–59
   PubMed Web of Science ®Google Scholar
• Baumann CR, Bassetti CL. Hypocretins (orexins) and sleep—wake disorders. Lancet Neurol 2005; 4: 673–682
   PubMed Web of Science ®Google Scholar
• Rejdak K, Petzold A, Lin L, et al. Decreased CSF hypocretin-1 (orexin-A) in patients after acute haemorrhagic brain injury. J Neurol Neurosurg Psychiatry 2005; 76: 597–598
   PubMed Web of Science ®Google Scholar
• Ogden JA, Mee E, Henning M. A prospective study of psychosocial adaptation following subarachnoid haemorrhage. Neuropsychol Rehabil 1994; 4: 7–30
   Google Scholar
• Baumann CR, Stocker R, Imhof HG, et al. Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology 2005; 65: 147–109
   PubMed Web of Science ®Google Scholar
• Ang BT, Tan WL, Lim J, et al. Cerebrospinal fluid orexin in aneurysmal subarachnoid haemorrhage — a pilot study. J Clin Neurosci 2005; 12: 758–762
   PubMed Web of Science ®Google Scholar
• Doherty MJ, Watson NF, Hallam DK, et al. Ventricular cerebrospinal fluid hypocretin-1 inversely correlates with glucose levels in cerebrospinal fluid and serum from patients with neurological injuries. Neurocrit Care 2005; 3: 230–203
   PubMed Web of Science ®Google Scholar
• Overeem S, Dalmau J, Bataller L, et al. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 2004; 62: 138–140
   PubMed Web of Science ®Google Scholar
• Castillo PR, Mignot E, Woodruff BK, et al. Undetectable CSF hypocretin-1 in Hashimoto's encephalopathy associated with coma. Neurology 2004; 62: 1909–1900
   PubMed Web of Science ®Google Scholar
• Grady SP, Nishino S, Czeisler CA, et al. Diurnal variation in CSF orexin-A in healthy male subjects. Sleep 2006; 29: 295–207
   PubMed Web of Science ®Google Scholar
• Cardali S, Maugeri R. Detection of alphall-spectrin and break-down products in humans after severe traumatic brain injury. J Neurosurg Sci 2006; 50: 25–31
   PubMedGoogle Scholar
• Farkas O, Polgar B, Szekeres-Bartho J, et al. Spectrin breakdown products in the cerebrospinal fluid in severe head injury — preliminary observations. Acta Neurochir 2005; 147: 855–861
   PubMed Web of Science ®Google Scholar
• Siman R, McIntosh TK, Soltesz KM, et al. Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol Dis 2004; 16: 311–320
   PubMed Web of Science ®Google Scholar
• Bennett V, Gilligan DM. The spectrin-based membrane skeleton and micron-scale organization of the plasma membrane. Annu Rev Cell Biol 1993; 9: 27–66
   PubMedGoogle Scholar
• Pineda JA, Lewis SB, Valadka AB, et al. Clinical significance of alphall-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. ] Neurotrauma 2007; 24: 354–366
   PubMed Web of Science ®Google Scholar
• Satchell MA, Lai Y, Kochanek PM, et al. Cytochrome c, a biomarker of apoptosis, is increased in cerebrospinal fluid from infants with inflicted brain injury from child abuse.] Cereb Blood Flow Metab 2005; 25: 919–927
   PubMed Web of Science ®Google Scholar
• Seki Y, Kimura M, Mizutani N, et al. Cerebrospinal fluid taurine after traumatic brain injury. Neurochem Res 2005; 30: 123–108
   PubMed Web of Science ®Google Scholar
• Stover JF, Unterberg AW. Increased cerebrospinal fluid glutamate and taurine concentrations are associated with traumatic brain edema formation in rats. Brain Res 2000; 875: 51–55
   PubMed Web of Science ®Google Scholar
• Stover JF, Morganti-Kosmann MC, Lenzlinger PM, et al. Glutamate and taurine are increased in ventricular cerebrospinal fluid of severely brain-injured patients. ] Neurotrauma 1999; 16: 135-142
   PubMed Web of Science ®Google Scholar
• Kirchhoff C, Stegmaier J, Bogner V, eta,'. Intrathecal and systemic concentration of NT-proBNP in patients with severe traumatic brain injury. ] Neurotrauma 2006; 23: 943–909
   PubMed Web of Science ®Google Scholar
• Majetschak M, King DR, Krehmeier U, et al. Ubiquitin immunoreactivity in cerebrospinal fluid after traumatic brain injury: Clinical and experimental findings. Crit Care Med 2005; 33: 1589–1594
   PubMed Web of Science ®Google Scholar
• Aitken A. 14-3-3 proteins: A historic overview. Semin Cancer Biol 2006; 16: 162–172
   PubMed Web of Science ®Google Scholar
• van Heusden GP. 14-3-3 proteins: Regulators of numerous eukaryotic proteins. IUBMB Life 2005; 57: 623–609
   PubMed Web of Science ®Google Scholar
• Bridges D, Moorhead GB. 14-3-3 proteins: A number of functions for a numbered protein. Sci STKE 2005; 2005: re10
   Google Scholar
• Mhawech P. 14-3-3 proteins — an update. Cell Res 2005; 15: 228–236
   PubMed Web of Science ®Google Scholar
• Boston PF, Jackson P, Thompson RJ. Human 14-3-3 protein: Radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders.] Neurochem 1982; 38: 1475–1482
   PubMed Web of Science ®Google Scholar
• Satoh J, Kurohara K, Yukitake M, et al. The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture. Eur Neurol 1999; 41: 216–225
   PubMed Web of Science ®Google Scholar
• Green AJ, Ramljak S, Muller WE, et al. 14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt-Jakob disease measured using capture assay able to detect low levels of 14-3-3 protein. Neurosci Lett 2002; 324: 57–60
   PubMed Web of Science ®Google Scholar
• Green AJ, Thompson EJ, Stewart GE, et al. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt—Jakob disease. ] Neurol Neurosurg Psychiatry 2001; 70: 744–748
   PubMed Web of Science ®Google Scholar
• Bersano A, Fiorini M, Allaria S, et al. Detection of CSF 14-3-3 protein in Guillain—Barre syndrome. Neurology 2006; 67: 2211–2206
   PubMed Web of Science ®Google Scholar
• Vander T, Hallevy C, Alsaed I, et al. 14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy. J Neurol 2004; 251: 1273–1204
   PubMed Web of Science ®Google Scholar
• Hernandez-Echebarria LE, Saiz A, Graus F, et al. Detection of 14-3-3 protein in the CSF of a patient with Hashimoto's encephalo-pathy. Neurology 2000; 54: 1539–1540
   PubMed Web of Science ®Google Scholar
• Bonora S, Zanusso G, Raiteri R, et al. Clearance of 14-3-3 protein from cerebrospinal fluid heralds the resolution of bacterial meningitis. Clin Infect Dis 2003; 36: 1492–1405
   PubMed Web of Science ®Google Scholar
• Finsterer J, Voigtlander T. Elevated 14-3-3 protein and axonal loss in immunoglobulin-responsive, idiopathic acute transverse mye-litis. Clin Neurol Neurosurg 2002; 105: 18–22
   PubMed Web of Science ®Google Scholar
• Grigelioniene G, Blennow M, Torok C, et al. Cerebrospinal fluid of newborn infants contains a deglycosylated form of the intermediate filament nestin. Pediatr Res 1996; 40: 809–814
   PubMed Web of Science ®Google Scholar
• Abboud H, Labreuche J, Meseguer E, et al. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis 2007; 23: 216–220
   PubMed Web of Science ®Google Scholar
• Jauch EC, Lindsell C, Broderick J, et al. Association of serial biochemical markers with acute ischemic stroke: The National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. Stroke 2006; 37: 2508–2513
   PubMed Web of Science ®Google Scholar
• Sartori M, Benetton V, Carraro AM, et al. Blood pressure in acute ischemic stroke and mortality: A study with noninvasive blood pressure monitoring. Blood Press Monit 2006; 11: 199–205
   PubMed Web of Science ®Google Scholar
• Lippi G, Salvagno GL, Montagnana M, et al., Influence of physical exercise and relationship with biochemical variables of NT-pro-brain natriuretic peptide and ischemia modified albumin. Clin Chim Acta 2006; 367: 175–180
   PubMed Web of Science ®Google Scholar
• Lippi G, Brocco G, Salvagno GL, et al. High-workload endurance training may increase serum ischemia-modified albumin con-centrations. Clin Chem Lab Med 2005; 43: 741–704
   PubMed Web of Science ®Google Scholar
• Cherubini A, Ruggiero C, Polidori MC, et al. Potential markers of oxidative stress in stroke. Free Radic Biol Med 2005; 39: 841–852
   PubMed Web of Science ®Google Scholar
• Rejdak K, Petzold A, Sharpe MA, et al. Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury. ] Neurol Sci 2003; 208: 1–7
   PubMed Web of Science ®Google Scholar
• Miranda KM, Espey MG, Wink DA. A rapid, simple spectro-photometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001; 5: 62–71
   PubMed Web of Science ®Google Scholar
• Keynes RG, Garthwaite J. Nitric oxide and its role in ischaemic brain injury. Curr Mol Med 2004; 4: 179–191
   PubMed Web of Science ®Google Scholar
• Moncada S, Bolanos JP. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 2006; 97: 1676-1689
   PubMed Web of Science ®Google Scholar
• Moro MA, Cardenas A, Hurtado O, et al. Role of nitric oxide after brain ischaemia. Cell Calcium 2004; 36: 265–275
   PubMed Web of Science ®Google Scholar
• Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990; 11: 379–387
   PubMed Web of Science ®Google Scholar
• Palmer AM, Marion DW, Botscheller ML, et al. Increased transmitter amino acid concentration in human ventricular CSF after brain trauma. Neuroreport 1994; 6: 153–106
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang X, Zhang T, et al. Excitatory amino acids in cerebrospinal fluid of patients with acute head injuries. Clin Chem 2001; 47: 1458–1462
   PubMed Web of Science ®Google Scholar
• Stover JF, Schoning B, Beyer TF, et al. Temporal profile of cerebrospinal fluid glutamate, interleukin-6, and tumor necrosis factor-alpha in relation to brain edema and contusion following controlled cortical impact injury in rats. Neurosci Lett 2000; 288: 25–28
   PubMed Web of Science ®Google Scholar
• Ruppel RA, Kochanek PM, Adelson PD, et al. Excitatory amino acid concentrations in ventricular cerebrospinal fluid after severe traumatic brain injury in infants and children: The role of child abuse. J Pediatr 2001; 138: 18–25
   PubMed Web of Science ®Google Scholar
• Polidori MC, Cherubini A, Stahl W, et al. Plasma carotenoid and malondialdehyde levels in ischemic stroke patients: Relationship to early outcome. Free Radic Res 2002; 36: 265–208
   PubMed Web of Science ®Google Scholar
• Phillis JW, O'Regan MH. The role of phospholipases, cycloox-ygenases, and 1 ipoxygenases in cerebral ischemic/traumatic injuries. Crit Rev Neurobiol 2003; 15: 61–90
   PubMedGoogle Scholar
• Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl. Acad Sci USA 1990; 87: 9383–9307
   PubMed Web of Science ®Google Scholar
• Rokach J, Kim S, Bel lone S, et al. Total synthesis of isoprostanes: Discovery and quantitation in biological systems. Chem Phys Lipids 2004; 128: 35–56
   PubMed Web of Science ®Google Scholar
• Basu S, Helmersson J. Factors regulating isoprostane formation in vivo. Antioxid Redox Signal 2005; 7: 221–235
   PubMed Web of Science ®Google Scholar
• Cracowski JL.Isoprostanes:Anemergingroleinvascular physiology and disease? Chem Phys Lipids 2004; 128: 75–83
   PubMed Web of Science ®Google Scholar
• Lin CL, Hsu YT, Lin TK, et al. Increased levels of F2-isoprostanes following aneurysmal subarachnoid hemorrhage in humans. Free Radic Biol Med 2006; 40: 1466–1473
   PubMed Web of Science ®Google Scholar
• Bayir H, Marion DW, Puccio AW, et al. Marked gender effect on lipid peroxidation after severe traumatic brain injury in adult patients. ] Neurotrauma 2004; 21: 1–8
   PubMed Web of Science ®Google Scholar
• Varma S, Janesko KL, Wisniewski SR, et al. F2-isoprostane and neuron-specific enolase in cerebrospinal fluid after severe traumatic brain injury in infants and children. J Neurotrauma 2003; 20: 781–706
   PubMed Web of Science ®Google Scholar
• Wagner AK, Bayir H, Ren D, et al. Relationships between cerebrospinal fluid markers of excitotoxicity, ischemia, and oxidative damage after severe TBI: The impact of gender, age, and hypothermia. ] Neurotrauma 2004; 21: 125–136
   PubMed Web of Science ®Google Scholar
• Veerkamp JH, Zimmerman AW. Fatty acid-binding proteins of nervous tissue. J Mol Neurosci 2001; 16: 133–142
   PubMed Web of Science ®Google Scholar
• Steinacker P, Mollenhauer B, Bibl M, et al. Heart fatty acid binding protein as a potential diagnostic marker for neurodegen-erative diseases. Neurosci Lett 2004; 370: 36–39
   PubMed Web of Science ®Google Scholar
• Wunderlich MT, Hanhoff T, Goertler M, et al. Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol 2005; 252: 718–724
   PubMed Web of Science ®Google Scholar
• Zimmermann-lvol CG, Burkhard PR, Le Floch-Rohr J, et al. Fatty acid binding protein as a serum marker for the early diagnosis of stroke: A pilot study. Mol Cell Proteomics 2004; 3: 66–72
   PubMed Web of Science ®Google Scholar
• Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol 2005; 5: 629–640
   PubMed Web of Science ®Google Scholar
• Petzold A, Downie P, Smith M. Critical illness brain syndrome (CIBS): An underestimated entity? Crit Care Med 2005; 33: 1464
   PubMed Web of Science ®Google Scholar
• Hopkins RO, Jackson JC. Long-term neurocognitive function after critical illness. Chest 2006; 130: 869–878
   PubMed Web of Science ®Google Scholar
• Stevens RD, Pronovost PJ. The spectrum of encephalopathy in critical illness. Semin Neurol 2006; 26: 440–451
   PubMed Web of Science ®Google Scholar
• Conti A, Sanchez-Ruiz Y, Bachi A, et al. Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin(ogen) degradation products as trauma-associated markers. Neurotrauma 2004; 21: 854–863
   PubMed Web of Science ®Google Scholar
• Gao WM, Chadha MS, Berger RP, et al. A gel-based proteomic comparison of human cerebrospinal fluid between inflicted and non-inflicted pediatric traumatic brain injury. I Neurotrauma 2007; 24: 43–53
   PubMed Web of Science ®Google Scholar
• Burgess JA, Lescuyer P, Hainard A, et al. Identification of brain cell death associated proteins in human post-mortem cerebrosp-inal fluid. J Proteome Res 2006; 5: 1674–1681
   PubMed Web of Science ®Google Scholar
• Albers JW, Kelly JJ, Jr. Acquired inflammatory demyelinating polyneuropathies: Clinical and electrodiagnostic features. Muscle Nerve 1989; 12: 435–451
   PubMed Web of Science ®Google Scholar